Title |
Is My Patient Taking an Unsafe Dietary Supplement?
|
---|---|
Published in |
The AMA Journal of Ethic, May 2022
|
DOI | 10.1001/amajethics.2022.390 |
Pubmed ID | |
Authors |
Ilisa B G Bernstein, Karin L Bolte |
Abstract |
Dietary supplements do not require premarket approval by the US Food and Drug Administration (FDA), yet they can have side effects; interact with medications, food, or other supplements; or be unsafe, so it is important for clinicians to discuss dietary supplement use with patients. This article provides an overview of dietary supplement requirements related to safety, manufacturing, labeling, advertising, and adverse event reporting; discusses tainted supplements and the FDA's and Federal Trade Commission's enforcement actions against dietary supplements; and offers recommendations to clinicians on matters of key clinical and ethical importance during clinical encounters. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 43% |
India | 1 | 14% |
Unknown | 3 | 43% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 57% |
Practitioners (doctors, other healthcare professionals) | 2 | 29% |
Science communicators (journalists, bloggers, editors) | 1 | 14% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 1 | 50% |
Unknown | 1 | 50% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 50% |
Unknown | 1 | 50% |